Basic Information
Ritonavir Viatris (previously Ritonavir Mylan)
Regulatory Information
EMEA/H/C/004549
November 9, 2017
September 14, 2017
17
September 11, 2024
Company Information
Ireland
Damastown Industrial Park Dublin 15
VIATRIS PHARMA LIMITED
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older).
Overview Summary
This is a summary of the European public assessment report (EPAR) for Ritonavir Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ritonavir Mylan. For practical information about using Ritonavir Mylan, patients should read the package leaflet or contact their doctor or pharmacist.